Overview of Lung Transplantation and Criteria for Selection of Candidates

ABSTRACT

Lung or heart-lung transplantation is a viable option for diverse end-stage pulmonary parenchymal or pulmonary vascular disorders. However, mortality associated with lung transplant (LT) is appreciable, with 3 and 5 year survival rates of ~60 and 50%, respectively. Thus LT is reserved for patients with life-threatening disease refractory to medical therapy. Four diagnoses (i.e., chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; cystic fibrosis; α-1-antitrypsin deficiency emphysema) account for ~80% of LT recipients; diverse interstitial and pulmonary vascular disorders account for the remaining cases. Given the potential morbidity and mortality associated with LT, the decision to refer patients for LT is difficult. Which patients are acceptable candidates for LT? What are the projected benefits of LT? What criteria should be used to estimate mortality with medical therapy alone? Given the uncertainty of waiting time, when should patients be listed for LT? Identifying appropriate candidates for LT and determining when to list for LT is determined by a risk analysis of the likelihood of mortality during the projected waiting period versus the likely mortality following LT. In this review, we discuss the major diseases treated with LT and the appropriate criteria for LT.

KEYWORDS

Lung transplant - chronic obstructive lung disease - emphysema - cystic fibrosis - idiopathic pulmonary fibrosis (IPF) - nonspecific interstitial pneumonia (NSIP) - collagen vascular diseases - pulmonary fibrosis - sarcoidosis - pulmonary arterial hypertension

REFERENCES

• 1 Rutherford R, Lordan J L, Fisher A J, Corris P A. Historical overview of lung and heart-lung transplantation. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor Francis 2006: 1-20
• 2 Arcasoy S M, Kotloff R M. Lung transplantation.  N Engl J Med. 1999;  340 1081-1091
• 3 The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT) . International guidelines for the selection of lung transplant candidates.  Am J Respir Crit Care Med. 1998;  158 335-339
• 4 Estenne M, Kotloff R M. Update in transplantation 2005.  Am J Respir Crit Care Med. 2006;  173 593-598
• 5 Reitz B A, Wallwork J L, Hunt S A et al.. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.  N Engl J Med. 1982;  306 557-564
• 6 Dennis C, Caine N, Sharples L et al.. Heart-lung transplantation for end-stage respiratory disease in patients with cystic fibrosis at Papworth Hospital.  J Heart Lung Transplant. 1993;  12(6 Pt 1) 893-902
• 7 Shennib H, Noirclerc M, Ernst P et al.. Double-lung transplantation for cystic fibrosis. The Cystic Fibrosis Transplant Study Group.  Ann Thorac Surg. 1992;  54 27-31 discussion 32
• 8 Oaks T E, Aravot D, Dennis C, Wells F C, Large S R, Wallwork J. Domino heart transplantation: the Papworth experience.  J Heart Lung Transplant. 1994;  13 433-437
• 9 Toronto Lung Transplant Group . Unilateral lung transplantation for pulmonary fibrosis.  N Engl J Med. 1986;  314 1140-1145
• 10 Cooper J D, Patterson G A, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease.  Am Rev Respir Dis. 1989;  139 303-307
• 11 Pasque M K, Cooper J D, Kaiser L R, Haydock D A, Triantafillou A, Trulock E P. Improved technique for bilateral lung transplantation: rationale and initial clinical experience.  Ann Thorac Surg. 1990;  49 785-791
• 12 Trulock E P, Edwards L B, Taylor D O, Boucek M M, Keck B M, Hertz M I. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005.  J Heart Lung Transplant. 2005;  24 956-967
• 13 Hosenpud J D, Bennett L E, Keck B M, Edwards E B, Novick R J. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease.  Lancet. 1998;  351 24-27
• 14 Stavem K, Bjortuft O, Borgan O, Geiran O, Boe J. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit.  J Heart Lung Transplant. 2006;  25 75-84
• 15 De Meester J, Smits J M, Persijn G G, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience.  J Heart Lung Transplant. 2001;  20 518-524
• 16 Liou T G, Adler F R, Cahill B C et al.. Survival effect of lung transplantation among patients with cystic fibrosis.  JAMA. 2001;  286 2683-2689
• 17 Thabut G, Mal H, Castier Y et al.. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.  J Thorac Cardiovasc Surg. 2003;  126 469-475
• 18 Charman S C, Sharples L D, McNeil K D, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis.  J Heart Lung Transplant. 2002;  21 226-232
• 19 TenVergert E M, Essink-Bot M L, Geertsma A, van Enckevort P J, de Boer W J, van der Bij W. The effect of lung transplantation on health-related quality of life: a longitudinal study.  Chest. 1998;  113 358-364
• 20 Lanuza D M, Lefaiver C, Mc Cabe M, Farcas G A, Garrity Jr E. Prospective study of functional status and quality of life before and after lung transplantation.  Chest. 2000;  118 115-122
• 21 MacNaughton K L, Rodrigue J R, Cicale M, Staples E M. Health-related quality of life and symptom frequency before and after lung transplantation.  Clin Transplant. 1998;  12 320-323
• 22 TenVergert E M, Vermeulen K M, Geertsma A et al.. Quality of life before and after lung transplantation in patients with emphysema versus other indications.  Psychol Rep. 2001;  89 707-717
• 23 Anyanwu A C, McGuire A, Rogers C A, Murday A J. An economic evaluation of lung transplantation.  J Thorac Cardiovasc Surg. 2002;  123 411-418 discussion 418-420
• 24 Ouwens J P, van Enckevort P J, TenVergert E M et al.. The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands.  Transpl Int. 2003;  16 123-127
• 25 Egan T, Edwards L B, Coke M A, Murray S, Shearon T H, Bustami R. Lung allocation in the United States. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor Francis 2006: 285-300
• 26 Kotloff R, Martinez F. Lung transplantation for chronic obstructive pulmonary disease. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor and Francis 2006: 61-120
• 27 Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.  Am J Respir Crit Care Med. 2001;  163 1256-1276
• 28 Barnes P J. Chronic obstructive pulmonary disease.  N Engl J Med. 2000;  343 269-280
• 29 Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.  Eur Respir J. 2004;  23 932-946
• 30 American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1995;  152(5 Pt 2) S77-121
• 31 Ferguson G T. Recommendations for the management of COPD.  Chest. 2000;  117(Suppl 2) 23S-28S
• 32 Burchfiel C M, Marcus E B, Curb J D et al.. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function.  Am J Respir Crit Care Med. 1995;  151 1778-1785
• 33 Pelkonen M, Tukiainen H, Tervahauta M et al.. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men.  Thorax. 2000;  55 746-750
• 34 James A L, Palmer L J, Kicic E et al.. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking.  Am J Respir Crit Care Med. 2005;  171 109-114
• 35 Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma.  N Engl J Med. 1998;  339 1194-1200
• 36 Celli B R, Cote C G, Marin J M et al.. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 1005-1012
• 37 Weder M M, Donohue J F. Role of bronchodilators in chronic obstructive pulmonary disease.  Semin Respir Crit Care Med. 2005;  26 221-234
• 38 Sin D D, McAlister F A, Man S F, Anthonisen N R. Contemporary management of chronic obstructive pulmonary disease: scientific review.  JAMA. 2003;  290 2301-2312
• 39 Casaburi R, Kukafka D, Cooper C B, Witek Jr T J, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.  Chest. 2005;  127 809-817
• 40 Pompeo E, Marino M, Nofroni I, Matteucci G, Mineo T C. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Pulmonary Emphysema Research Group.  Ann Thorac Surg. 2000;  70 948-953 discussion 954
• 41 Nici L, Donner C, Wouters E et al.. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.  Am J Respir Crit Care Med. 2006;  173 1390-1413
• 42 Ries A L. Pulmonary rehabilitation and COPD.  Semin Respir Crit Care Med. 2005;  26 133-141
• 43 Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease.  Semin Respir Crit Care Med. 2005;  26 192-203
• 44 Cooper C B, Tashkin D P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease.  BMJ. 2005;  330 640-644
• 45 Calverley P M. The role of corticosteroids in chronic obstructive pulmonary disease.  Semin Respir Crit Care Med. 2005;  26 235-245
• 46 Crockett A J, Cranston J M, Moss J R, Alpers J H. A review of long-term oxygen therapy for chronic obstructive pulmonary disease.  Respir Med. 2001;  95 437-443
• 47 Wijkstra P J, Lacasse Y, Guyatt G H et al.. A meta-analysis of nocturnal noninvasive positive pressure ventilation in patients with stable COPD.  Chest. 2003;  124 337-343
• 48 Traver G A, Cline M G, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease: a 15-year follow-up study.  Am Rev Respir Dis. 1979;  119 895-902
• 49 Burrows B, Earle R H. Prediction of survival in patients with chronic airway obstruction.  Am Rev Respir Dis. 1969;  99 865-871
• 50 Anthonisen N R, Wright E C, Hodgkin J E. Prognosis in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1986;  133 14-20
• 51 Anthonisen N R. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials.  Am Rev Respir Dis. 1989;  140(3 Pt 2) S95-S99
• 52 Piccioni P, Caria E, Bignamini E et al.. Predictors of survival in a group of patients with chronic airflow obstruction.  J Clin Epidemiol. 1998;  51 547-555
• 53 Hansen E F, Phanareth K, Laursen L C, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  159(4 Pt 1) 1267-1271
• 54 Thomason M J, Strachan D P. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease?.  Thorax. 2000;  55 785-788
• 55 Cooper C B, Waterhouse J, Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy.  Thorax. 1987;  42 105-110
• 56 Postma D S, Burema J, Gimeno F et al.. Prognosis in severe chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1979;  119 357-367
• 57 Martinez F J, Kotloff R. Prognostication in chronic obstructive pulmonary disease: implications for lung transplantation.  Semin Respir Crit Care Med. 2001;  22 489-498
• 58 Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu J M. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation: a 10-year analysis of ANTADIR Observatory.  Chest. 1996;  109 741-749
• 59 Nocturnal Oxygen Therapy Trial Group . Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.  Ann Intern Med. 1980;  93 391-398
• 60 Foucher P, Baudouin N, Merati M et al.. Relative survival analysis of 252 patients with COPD receiving long-term oxygen therapy.  Chest. 1998;  113 1580-1587
• 61 Kanner R E, Renzetti Jr A D, Stanish W M, Barkman Jr H W, Klauber M R. Predictors of survival in subjects with chronic airflow limitation.  Am J Med. 1983;  74 249-255
• 62 Connors Jr A F, Dawson N V, Thomas C et al.. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments).  Am J Respir Crit Care Med. 1996;  154(4 Pt 1) 959-967
• 63 Aida A, Miyamoto K, Nishimura M, Aiba M, Kira S, Kawakami Y. Prognostic value of hypercapnia in patients with chronic respiratory failure during long-term oxygen therapy.  Am J Respir Crit Care Med. 1998;  158 188-193
• 64 Costello R, Deegan P, Fitzpatrick M, McNicholas W T. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis.  Am J Med. 1997;  102 239-244
• 65 National Emphysema Treatment Trial Research Group . Patients at high risk of death after lung-volume-reduction surgery.  N Engl J Med. 2001;  345 1075-1083
• 66 Wright J L, Levy R D, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.  Thorax. 2005;  60 605-609
• 67 Oswald-Mammosser M, Weitzenblum E, Quoix E et al.. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure.  Chest. 1995;  107 1193-1198
• 68 Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment.  Proc Am Thorac Soc. 2005;  2 12-19
• 69 Pinto-Plata V M, Cote C, Cabral H, Taylor J, Celli B R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.  Eur Respir J. 2004;  23 28-33
• 70 Bowen J B, Votto J J, Thrall R S et al.. Functional status and survival following pulmonary rehabilitation.  Chest. 2000;  118 697-703
• 71 Gerardi D A, Lovett L, Benoit-Connors M L, Reardon J Z, ZuWallack R L. Variables related to increased mortality following out-patient pulmonary rehabilitation.  Eur Respir J. 1996;  9 431-435
• 72 Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status.  Am J Respir Crit Care Med. 2003;  167 544-549
• 73 Hiraga T, Maekura R, Okuda Y et al.. Prognostic predictors for survival in patients with COPD using cardiopulmonary exercise testing.  Clin Physiol Funct Imaging. 2003;  23 324-331
• 74 Vestbo J, Prescott E, Almdal T et al.. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study.  Am J Respir Crit Care Med. 2006;  173 79-83
• 75 Marti S, Munoz X, Rios J, Morell F, Ferrer J. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy.  Eur Respir J. 2006;  27 689-696
• 76 Madill J, Gutierrez C, Grossman J et al.. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation.  J Heart Lung Transplant. 2001;  20 288-296
• 77 Gray-Donald K, Gibbons L, Shapiro S H, Macklem P T, Martin J G. Nutritional status and mortality in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1996;  153 961-966
• 78 Schols A M, Slangen J, Volovics L, Wouters E F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  157(6 Pt 1) 1791-1797
• 79 Landbo C, Prescott E, Lange P, Vestbo J, Almdal T P. Prognostic value of nutritional status in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 1856-1861
• 80 Marquis K, Debigare R, Lacasse Y et al.. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2002;  166 809-813
• 81 Prescott E, Almdal T, Mikkelsen K L, Tofteng C L, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study.  Eur Respir J. 2002;  20 539-544
• 82 Soler-Cataluna J J, Sanchez-Sanchez L, Martinez-Garcia M A, Sanchez P R, Salcedo E, Navarro M. Mid-arm muscle area is a better predictor of mortality than body mass index in COPD.  Chest. 2005;  128 2108-2115
• 83 Hunninghake D B. Cardiovascular disease in chronic obstructive pulmonary disease.  Proc Am Thorac Soc. 2005;  2 44-49
• 84 Antonelli Incalzi R, Fuso L, De Rosa M et al.. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.  Eur Respir J. 1997;  10 2794-2800
• 85 Celli B R, Calverley P M, Rennard S I et al.. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease.  Respir Med. 2005;  99 1546-1554
• 86 Martinez F J, Foster G, Curtis J L et al.. Predictors of mortality in patients with emphysema and severe airflow obstruction.  Am J Respir Crit Care Med. 2006;  173 1326-1334
• 87 Cooper J D, Trulock E P, Triantafillou A N et al.. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease.  J Thorac Cardiovasc Surg. 1995;  109 106-116 discussion 116-119
• 88 Hardoff R, Shitrit D, Tamir A, Steinmetz A P, Krausz Y, Kramer M R. Short- and long-term outcome of lung volume reduction surgery: the predictive value of the preoperative clinical status and lung scintigraphy.  Respir Med. 2006;  100 1041-1049
• 89 Miller J D, Malthaner R A, Goldsmith C H et al.. A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada.  Ann Thorac Surg. 2006;  81 314-320 discussion 320-321
• 90 Naunheim K S, Wood D E, Krasna M J et al.. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial.  J Thorac Cardiovasc Surg. 2006;  131 43-53
• 91 Martinez F J, Chang A. Surgical therapy for chronic obstructive pulmonary disease.  Semin Respir Crit Care Med. 2005;  26 167-191
• 92 Miller J D, Berger R L, Malthaner R A et al.. Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema.  Chest. 2005;  127 1166-1177
• 93 Geddes D, Davies M, Koyama H et al.. Effect of lung-volume-reduction surgery in patients with severe emphysema.  N Engl J Med. 2000;  343 239-245
• 94 Leyenson V, Furukawa S, Kuzma A M, Cordova F, Travaline J, Criner G J. Correlation of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise, and gas exchange.  Chest. 2000;  118 728-735
• 95 Yusen R D, Lefrak S S, Gierada D S et al.. A prospective evaluation of lung volume reduction surgery in 200 consecutive patients.  Chest. 2003;  123 1026-1037
• 96 Flaherty K R, Kazerooni E A, Curtis J L et al.. Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT.  Chest. 2001;  119 1337-1346
• 97 Cooper J D, Patterson G A, Sundaresan R S et al.. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema.  J Thorac Cardiovasc Surg. 1996;  112 1319-1329 discussion 1329-1330
• 98 Young J, Fry-Smith A, Hyde C. Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema.  Thorax. 1999;  54 779-789
• 99 Fessler H E, Wise R A. Lung volume reduction surgery: is less really more?.  Am J Respir Crit Care Med. 1999;  159(4 Pt 1) 1031-1035
• 100 Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery.  J Thorac Cardiovasc Surg. 1999;  118 518-528
• 101 Fishman A, Martinez F, Naunheim K et al.. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.  N Engl J Med. 2003;  348 2059-2073
• 102 McKenna Jr R J, Benditt J O, DeCamp M et al.. Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery.  J Thorac Cardiovasc Surg. 2004;  127 1350-1360
• 103 McKenna Jr R J, Brenner M, Fischel R J et al.. Patient selection criteria for lung volume reduction surgery.  J Thorac Cardiovasc Surg. 1997;  114 957-964 discussion 964-967
• 104 Ingenito E P, Loring S H, Moy M L et al.. Comparison of physiological and radiological screening for lung volume reduction surgery.  Am J Respir Crit Care Med. 2001;  163 1068-1073
• 105 Pompeo E, Sergiacomi G, Nofroni I, Roscetti W, Simonetti G, Mineo T C. Morphologic grading of emphysema is useful in the selection of candidates for unilateral or bilateral reduction pneumoplasty.  Eur J Cardiothorac Surg. 2000;  17 680-686
• 106 Slone R M, Pilgram T K, Gierada D S et al.. Lung volume reduction surgery: comparison of preoperative radiologic features and clinical outcome.  Radiology. 1997;  204 685-693
• 107 Szekely L A, Oelberg D A, Wright C et al.. Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery.  Chest. 1997;  111 550-558
• 108 O'Brien G M, Furukawa S, Kuzma A M, Cordova F, Criner G J. Improvements in lung function, exercise, and quality of life in hypercapnic COPD patients after lung volume reduction surgery.  Chest. 1999;  115 75-84
• 109 Naunheim K S, Hazelrigg S R, Kaiser L R et al.. Risk analysis for thoracoscopic lung volume reduction: a multi-institutional experience.  Eur J Cardiothorac Surg. 2000;  17 673-679
• 110 Wisser W, Klepetko W, Kontrus M et al.. Morphologic grading of the emphysematous lung and its relation to improvement after lung volume reduction surgery.  Ann Thorac Surg. 1998;  65 793-799
• 111 Ciccone A M, Meyers B F, Guthrie T J et al.. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema.  J Thorac Cardiovasc Surg. 2003;  125 513-525
• 112 Wan I Y, Toma T P, Geddes D M et al.. Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients.  Chest. 2006;  129 518-526
• 113 Toma T P, Hopkinson N S, Hillier J et al.. Bronchoscopic volume reduction with valve implants in patients with severe emphysema.  Lancet. 2003;  361 931-933
• 114 Yim A P, Hwong T M, Lee T W et al.. Early results of endoscopic lung volume reduction for emphysema.  J Thorac Cardiovasc Surg. 2004;  127 1564-1573
• 115 Snell G I, Holsworth L, Borrill Z L et al.. The potential for bronchoscopic lung volume reduction using bronchial prostheses: a pilot study.  Chest. 2003;  124 1073-1080
• 116 Hopkinson N S, Toma T P, Hansell D M et al.. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema.  Am J Respir Crit Care Med. 2005;  171 453-460
• 117 Venuta F, de Giacomo T, Rendina E A et al.. Bronchoscopic lung-volume reduction with one-way valves in patients with heterogenous emphysema.  Ann Thorac Surg. 2005;  79 411-416 discussion 416-417
• 118 Sundaresan R S, Shiraishi Y, Trulock E P et al.. Single or bilateral lung transplantation for emphysema?.  J Thorac Cardiovasc Surg. 1996;  112 1485-1494 discussion 1494-1495
• 119 Meyer D M, Bennett L E, Novick R J, Hosenpud J D. Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points.  J Heart Lung Transplant. 2001;  20 935-941
• 120 Schnickel G, Ardehali A. Operative techniques utilized in lung transplantation and strategies to increase the donor pool. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor and Francis 2006: 349-362
• 121 Stoller J K, Aboussouan L S. Alpha1-antitrypsin deficiency.  Lancet. 2005;  365 2225-2236
• 122 Ranes J, Stoller J K. A review of alpha-1 antitrypsin deficiency.  Semin Respir Crit Care Med. 2005;  26 154-166
• 123 DeMeo D L, Silverman E K. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.  Thorax. 2004;  59 259-264
• 124 American Thoracic Society/European Respiratory Society Statement . Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.  Am J Respir Crit Care Med. 2003;  168 818-900
• 125 Stoller J K, Tomashefski Jr J, Crystal R G et al.. Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry.  Chest. 2005;  127 1196-1204
• 126 Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency.  Am J Respir Crit Care Med. 1995;  151(2 Pt 1) 369-373
• 127 Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist A S. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency.  J Pediatr. 1990;  116 248-251
• 128 Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases.  Thorax. 1994;  49 695-698
• 129 Turino G M, Barker A F, Brantly M L et al.. Clinical features of individuals with PI* SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.  Am J Respir Crit Care Med. 1996;  154(6 Pt 1) 1718-1725
• 130 The Alpha-1-Antitrypsin Deficiency Registry Study Group . Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin.  Am J Respir Crit Care Med. 1998;  158 49-59
• 131 Groen H, van der Bij W, Koeter G H, TenVergert E M. Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease.  Am J Transplant. 2004;  4 1155-1162
• 132 Mal H, Guignabert C, Thabut G et al.. Recurrence of pulmonary emphysema in an alpha-1 proteinase inhibitor-deficient lung transplant recipient.  Am J Respir Crit Care Med. 2004;  170 811-814
• 133 King M B, Campbell E J, Gray B H, Hertz M I. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients.  Am J Respir Crit Care Med. 1994;  149(4 Pt 1) 966-971
• 134 Meyer K C, Nunley D R, Dauber J H et al.. Neutrophils, unopposed neutrophil elastase, and alpha1-antiprotease defenses following human lung transplantation.  Am J Respir Crit Care Med. 2001;  164 97-102
• 135 Trulock E P. Lung transplantation for alpha 1-antitrypsin deficiency emphysema.  Chest. 1996;  110(Suppl 6) 284S-294S
• 136 Coakley R, Yankaskas J R. Lung transplant in cystic fibrosis. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor Francis 2006: 121-146
• 137 Yankaskas J R, Marshall B C, Sufian B, Simon R H, Rodman D. Cystic fibrosis adult care: consensus conference report.  Chest. 2004;  125(Suppl 1) 1S-39S
• 138 Trulock E P, Edwards L B, Taylor D O, Boucek M M, Keck B M, Hertz M I. The registry of the International Society for Heat and Lung Transplantation: twenty-first official adult heart transplant report-2004.  J Heart Lung Transplant. 2004;  23 804-815
• 139 Vizza C D, Yusen R D, Lynch J P, Fedele F, Alexander Patterson G, Trulock E P. Outcome of patients with cystic fibrosis awaiting lung transplantation.  Am J Respir Crit Care Med. 2000;  162(3 Pt 1) 819-825
• 140 Flume P A. Cystic fibrosis: when to consider lung transplantation?.  Chest. 1998;  113 1159-1161
• 141 Ciriaco P, Egan T M, Cairns E L, Thompson J T, Detterbeck F C, Paradowski L J. Analysis of cystic fibrosis referrals for lung transplantation.  Chest. 1995;  107 1323-1327
• 142 Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation.  J Heart Lung Transplant. 1993;  12 669-674
• 143 Yacoub M H, Banner N R, Khaghani A et al.. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation.  J Heart Transplant. 1990;  9 459-466 discussion 466-467
• 144 de Leval M R, Smyth R, Whitehead B et al.. Heart and lung transplantation for terminal cystic fibrosis: a 4 1/2-year experience.  J Thorac Cardiovasc Surg. 1991;  101 633-641 discussion 641-642
• 145 Yacoub M H, Gyi K, Khaghani A et al.. Analysis of 10-year experience with heart-lung transplantation for cystic fibrosis.  Transplant Proc. 1997;  29 632
• 146 Ganesh J S, Rogers C A, Bonser R S, Banner N R. Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study.  Eur Respir J. 2005;  25 964-969
• 147 Vricella L A, Karamichalis J M, Ahmad S, Robbins R C, Whyte R I, Reitz B A. Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience.  Ann Thorac Surg. 2002;  74 13-17 discussion 17-18
• 148 Egan T M, Detterbeck F C, Mill M R et al.. Long-term results of lung transplantation for cystic fibrosis.  Eur J Cardiothorac Surg. 2002;  22 602-609
• 149 Ramirez J C, Patterson G A, Winton T L, de Hoyos A L, Miller J D, Maurer J R. Bilateral lung transplantation for cystic fibrosis. The Toronto Lung Transplant Group.  J Thorac Cardiovasc Surg. 1992;  103 287-293 discussion 294
• 150 De Soyza A, Archer L, Wardle J et al.. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of perioperative sepsis.  J Heart Lung Transplant. 2003;  22 764-769
• 151 Mendeloff E N, Huddleston C B, Mallory G B et al.. Pediatric and adult lung transplantation for cystic fibrosis.  J Thorac Cardiovasc Surg. 1998;  115 404-413 discussion 413-414
• 152 Barlow C W, Robbins R C, Moon M R, Akindipe O, Theodore J, Reitz B A. Heart-lung versus double-lung transplantation for suppurative lung disease.  J Thorac Cardiovasc Surg. 2000;  119 466-476
• 153 Sharples L D, Scott J P, Dennis C et al.. Risk factors for survival following combined heart-lung transplantation. The first 100 patients.  Transplantation. 1994;  57 218-223
• 154 Starnes V A, Barr M L, Cohen R G et al.. Living-donor lobar lung transplantation experience: intermediate results.  J Thorac Cardiovasc Surg. 1996;  112 1284-1290 discussion 1290-1291
• 155 Starnes V A, Bowdish M E, Woo M S et al.. A decade of living lobar lung transplantation: recipient outcomes.  J Thorac Cardiovasc Surg. 2004;  127 114-122
• 156 Date H, Aoe M, Sano Y et al.. Improved survival after living-donor lobar lung transplantation.  J Thorac Cardiovasc Surg. 2004;  128 933-940
• 157 Bowdish M E, Barr M L. Living lobar lung transplantation. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor Francis 2006: 255-267
• 158 Forty J, Hasan A, Gould F K, Corris P A, Dark J H. Single-lung transplantation with simultaneous contralateral pneumonectomy for cystic fibrosis.  J Heart Lung Transplant. 1994;  13 727-730
• 159 Massard G, Shennib H, Metras D et al.. Double-lung transplantation in mechanically ventilated patients with cystic fibrosis.  Ann Thorac Surg. 1993;  55 1087-1091 discussion 1091-1092
• 160 Steinbach S, Sun L, Jiang R Z et al.. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis.  N Engl J Med. 1994;  331 981-987
• 161 Flume P A, Egan T M, Paradowski L J, Detterbeck F C, Thompson J T, Yankaskas J R. Infectious complications of lung transplantation: impact of cystic fibrosis.  Am J Respir Crit Care Med. 1994;  149 1601-1607
• 162 Kerem E, Reisman J, Corey M, Canny G J, Levison H. Prediction of mortality in patients with cystic fibrosis.  N Engl J Med. 1992;  326 1187-1191
• 163 Sharma R, Florea V G, Bolger A P et al.. Wasting as an independent predictor of mortality in patients with cystic fibrosis.  Thorax. 2001;  56 746-750
• 164 Milla C E, Warwick W J. Risk of death in cystic fibrosis patients with severely compromised lung function.  Chest. 1998;  113 1230-1234
• 165 Sood N, Paradowski L J, Yankaskas J R. Outcomes of intensive care unit care in adults with cystic fibrosis.  Am J Respir Crit Care Med. 2001;  163 335-338
• 166 Stanchina M L, Tantisira K G, Aquino S L, Wain J C, Ginns L C. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation.  J Heart Lung Transplant. 2002;  21 217-225
• 167 Venuta F, Rendina E A, Rocca G D et al.. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis.  J Thorac Cardiovasc Surg. 2000;  119(4 Pt 1) 682-689
• 168 Fraser K L, Tullis D E, Sasson Z, Hyland R H, Thornley K S, Hanly P J. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia.  Chest. 1999;  115 1321-1328
• 169 Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation.  J Heart Lung Transplant. 1997;  16 313-319
• 170 Tantisira K G, Systrom D M, Ginns L C. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation.  Am J Respir Crit Care Med. 2002;  165 1629-1633
• 171 Huang N N, Schidlow D V, Szatrowski T H et al.. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis.  Am J Med. 1987;  82 871-879
• 172 Snell G I, Bennetts K, Bartolo J et al.. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation.  J Heart Lung Transplant. 1998;  17 1097-1103
• 173 Liou T G, Adler F R, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis.  Am J Respir Crit Care Med. 2005;  171 1053-1059
• 174 LiPuma J J. Burkholderia and emerging pathogens in cystic fibrosis.  Semin Respir Crit Care Med. 2003;  24 681-692
• 175 Aris R M, Gilligan P H, Neuringer I P, Gott K K, Rea J, Yankaskas J R. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome.  Am J Respir Crit Care Med. 1997;  155 1699-1704
• 176 Helmi M, Love R B, Welter D, Cornwell R D, Meyer K C. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients.  Chest. 2003;  123 800-808
• 177 Nick J A. Nontuberculous mycobacteria in cystic fibrosis.  Semin Respir Crit Care Med. 2003;  24 693-702
• 178 Olivier K N, Weber D J, Lee J H et al.. Nontuberculous mycobacteria, II: Nested-cohort study of impact on cystic fibrosis lung disease.  Am J Respir Crit Care Med. 2003;  167 835-840
• 179 Fairhurst R M, Kubak B M, Shpiner R B, Levine M S, Pegues D A, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient.  J Heart Lung Transplant. 2002;  21 391-394
• 180 Sanguinetti M, Ardito F, Fiscarelli E et al.. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.  J Clin Microbiol. 2001;  39 816-819
• 181 Saggar S, Kubak B M, Ross D J, Lynch III J P. Mycobacterial infections complicating organ transplantation. In: Lynch JP III, Ross D Lung and Heart-Lung Transplantation. New York; Taylor and Francis 2006: 623-660
• 182 Dummer J S, Lazariashvilli N, Barnes J, Ninan M, Milstone A P. A survey of anti-fungal management in lung transplantation.  J Heart Lung Transplant. 2004;  23 1376-1381
• 183 Snell G I, de Hoyos A, Krajden M, Winton T, Maurer J R. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.  Chest. 1993;  103 466-471
• 184 Noyes B E, Michaels M G, Kurland G, Armitage J M, Orenstein D M. Pseudomonas cepacia empyema necessitatis after lung transplantation in two patients with cystic fibrosis.  Chest. 1994;  105 1888-1891
• 185 De Soyza A, McDowell A, Archer L et al.. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.  Lancet. 2001;  358 1780-1781
• 186 Chaparro C, Maurer J, Gutierrez C et al.. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.  Am J Respir Crit Care Med. 2001;  163 43-48
• 187 Ellaffi M, Vinsonneau C, Coste J et al.. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.  Am J Respir Crit Care Med. 2005;  171 158-164
• 188 Aris R M, Routh J C, LiPuma J J, Heath D G, Gilligan P H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type.  Am J Respir Crit Care Med. 2001;  164 2102-2106
• 189 Egan T M, Detterbeck F C, Mill M R et al.. Improved results of lung transplantation for patients with cystic fibrosis.  J Thorac Cardiovasc Surg. 1995;  109 224-234 discussion 234-235
• 190 de Perrot M, Chaparro C, McRae K et al.. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival.  J Thorac Cardiovasc Surg. 2004;  127 1493-1501
• 191 Tablan O C, Martone W J, Doershuk C F et al.. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes.  Chest. 1987;  91 527-532
• 192 Frangolias D D, Mahenthiralingam E, Rae S et al.. Burkholderia cepacia in cystic fibrosis: variable disease course.  Am J Respir Crit Care Med. 1999;  160(5 Pt 1) 1572-1577
• 193 Lewiston N, King V, Umetsu D et al.. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage.  Transplant Proc. 1991;  23(1 Pt 2) 1207-1208
• 194 Bosso J A, Saxon B A, Matsen J M. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.  Antimicrob Agents Chemother. 1990;  34 487-488
• 195 Burns J L, Saiman L. Burkholderia cepacia infections in cystic fibrosis.  Pediatr Infect Dis J. 1999;  18 155-156
• 196 Liou T G, Adler F R, Fitzsimmons S C, Cahill B C, Hibbs J R, Marshall B C. Predictive 5-year survivorship model of cystic fibrosis.  Am J Epidemiol. 2001;  153 345-352
• 197 Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C H, Aitken M L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.  Am J Respir Crit Care Med. 2002;  166(12 Pt 1) 1550-1555
• 198 Milross M A, Piper A J, Norman M et al.. Low-flow oxygen and bilevel ventilatory support: effects on ventilation during sleep in cystic fibrosis.  Am J Respir Crit Care Med. 2001;  163 129-134
• 199 Holzmann D, Speich R, Kaufmann T et al.. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience.  Transplantation. 2004;  77 134-136
• 200 Young L R, Hadjiliadis D, Davis R D, Palmer S M. Lung transplantation exacerbates gastroesophageal reflux disease.  Chest. 2003;  124 1689-1693
• 201 Beirne P A, Banner N R, Khaghani A, Hodson M E, Yacoub M H. Lung transplantation for non-cystic fibrosis bronchiectasis: analysis of a 13-year experience.  J Heart Lung Transplant. 2005;  24 1530-1535
• 202 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).  Am J Respir Crit Care Med. 2000;  161(2 Pt 1) 646-664
• 203 Gross T J, Hunninghake G W. Idiopathic pulmonary fibrosis.  N Engl J Med. 2001;  345 517-525
• 204 Katzenstein A L, Myers J L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.  Am J Respir Crit Care Med. 1998;  157(4 Pt 1) 1301-1315
• 205 Bjoraker J A, Ryu J H, Edwin M K et al.. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1998;  157 199-203
• 206 Nicholson A G, Wells A U. Nonspecific interstitial pneumonia: nobody said it's perfect.  Am J Respir Crit Care Med. 2001;  164 1553-1554
• 207 Travis W D, Matsui K, Moss J, Ferrans V J. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.  Am J Surg Pathol. 2000;  24 19-33
• 208 Mogulkoc N, Brutsche M H, Bishop P W, Greaves S M, Horrocks A W, Egan J J. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation.  Am J Respir Crit Care Med. 2001;  164 103-108
• 209 Douglas W W, Ryu J H, Schroeder D R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival.  Am J Respir Crit Care Med. 2000;  161 1172-1178
• 210 King Jr T E, Schwarz M I, Brown K et al.. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.  Am J Respir Crit Care Med. 2001;  164 1025-1032
• 211 Wells A U, Desai S R, Rubens M B et al.. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.  Am J Respir Crit Care Med. 2003;  167 962-969
• 212 Flaherty K R, Mumford J A, Murray S et al.. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 543-548
• 213 Flaherty K R, Colby T V, Travis W D et al.. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.  Am J Respir Crit Care Med. 2003;  167 1410-1415
• 214 Lynch III J P, Wurfel M, Flaherty K et al.. Usual interstitial pneumonia.  Semin Respir Crit Care Med. 2001;  22 357-387
• 215 Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis. A population-based cohort study.  Chest. 1998;  113 396-400
• 216 Nicholson A G, Colby T V, du Bois R M, Hansell D M, Wells A U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med. 2000;  162 2213-2217
• 217 Zisman D A, Lynch III J P, Toews G B, Kazerooni E A, Flint A, Martinez F J. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids.  Chest. 2000;  117 1619-1626
• 218 King Jr T E, Tooze J A, Schwarz M I, Brown K R, Cherniack R M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.  Am J Respir Crit Care Med. 2001;  164 1171-1181
• 219 Collard H R, King Jr T E, Bartelson B B, Vourlekis J S, Schwarz M I, Brown K K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2003;  168 538-542
• 220 Demedts M, Behr J, Buhl R et al.. High-dose acetylcysteine in idiopathic pulmonary fibrosis.  N Engl J Med. 2005;  353 2229-2242
• 221 Azuma A, Nukiwa T, Tsuboi E et al.. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2005;  171 1040-1047
• 222 Raghu G, Brown K K, Bradford W Z et al.. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.  N Engl J Med. 2004;  350 125-133
• 223 King Jr T E, Safrin S, Starko K M et al.. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.  Chest. 2005;  127 171-177
• 224 Selman M, Thannickal V J, Pardo A, Zisman D A, Martinez F J, Lynch III J P. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.  Drugs. 2004;  64 405-430
• 225 Thannickal V J, Toews G B, White E S, Lynch III J P, Martinez F J. Mechanisms of pulmonary fibrosis.  Annu Rev Med. 2004;  55 395-417
• 226 Thannickal V J, Flaherty K R, Martinez F J, Lynch III J P. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.  Expert Opin Pharmacother. 2004;  5 1671-1686
• 227 Thannickal V, Flaherty K, Hyzy R, Lynch III J P. Emerging drugs for idiopathic pulmonary fibrosis.  Expert Opin Emerg Drugs. 2005;  10 707-727
• 228 Flaherty K R, Martinez F J, Travis W, Lynch Iii J P. Nonspecific Interstitial Pneumonia (NSIP).  Semin Respir Crit Care Med. 2001;  22 423-434
• 229 Jegal Y, Kim D S, Shim T S et al.. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.  Am J Respir Crit Care Med. 2005;  171 639-644
• 230 MacDonald S L, Rubens M B, Hansell D M et al.. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT.  Radiology. 2001;  221 600-605
• 231 Nicholson A G, Fulford L G, Colby T V, du Bois R M, Hansell D M, Wells A U. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2002;  166 173-177
• 232 Flaherty K R, Travis W D, Colby T V et al.. Histopathologic variability in usual and nonspecific interstitial pneumonias.  Am J Respir Crit Care Med. 2001;  164 1722-1727
• 233 Latsi P I, du Bois R M, Nicholson A G et al.. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.  Am J Respir Crit Care Med. 2003;  168 531-537
• 234 Flaherty K R, Toews G B, Travis W D et al.. Clinical significance of histological classification of idiopathic interstitial pneumonia.  Eur Respir J. 2002;  19 275-283
• 235 Monaghan H, Wells A U, Colby T V, du Bois R M, Hansell D M, Nicholson A G. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias.  Chest. 2004;  125 522-526
• 236 Katzenstein A L, Zisman D A, Litzky L A, Nguyen B T, Kotloff R M. Usual interstitial pneumonia: histologic study of biopsy and explant specimens.  Am J Surg Pathol. 2002;  26 1567-1577
• 237 Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby T. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.  Eur Respir J. 1998;  12 1010-1019
• 238 Cottin V, Donsbeck A V, Revel D, Loire R, Cordier J F. Nonspecific interstitial pneumonia: individualization of a clinicopathologic entity in a series of 12 patients.  Am J Respir Crit Care Med. 1998;  158 1286-1293
• 239 Park J S, Lee K S, Kim J S et al.. Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in seven patients.  Radiology. 1995;  195 645-648
• 240 Meyer D M, Edwards L B, Torres F, Jessen M E, Novick R J. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis.  Ann Thorac Surg. 2005;  79 950-957 discussion 957-958
• 241 Shorr A F, Davies D B, Nathan S D. Outcomes for patients with sarcoidosis awaiting lung transplantation.  Chest. 2002;  122 233-238
• 242 Timmer S J, Karamzadeh A M, Yung G L, Kriett J, Jamieson S W, Smith C M. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does PaO predict survival?.  Chest. 2002;  122 779-784
• 243 Martinez F, Flaherty K, Travis W, Lynch III J P. Nonspecific interstitial pneumonia. In: Lynch JP III, guest Idiopathic Pulmonary Fibrosis. Vol 185. New York; Marcel Dekker 2004: 101-136
• 244 Schwartz D A, Helmers R A, Galvin J R et al.. Determinants of survival in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1994;  149(2 Pt 1) 450-454
• 245 Nadrous H F, Pellikka P A, Krowka M J et al.. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.  Chest. 2005;  128 2393-2399
• 246 Flaherty K R, Martinez F J. The role of pulmonary function testing in pulmonary fibrosis.  Curr Opin Pulm Med. 2000;  6 404-410
• 247 Lynch D A, Godwin J D, Safrin S et al.. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.  Am J Respir Crit Care Med. 2005;  172 488-493
• 248 Flaherty K R, Toews G B, Lynch III J P et al.. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.  Am J Med. 2001;  110 278-282
• 249 Gay S E, Kazerooni E A, Toews G B et al.. Idiopathic pulmonary fibrosis: predicting response to therapy and survival.  Am J Respir Crit Care Med. 1998;  157(4 Pt 1) 1063-1072
• 250 Lama V N, Flaherty K R, Toews G B et al.. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 1084-1090
• 251 Miki K, Maekura R, Hiraga T et al.. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis.  Respir Med. 2003;  97 482-490
• 252 Hallstrand T S, Boitano L J, Johnson W C, Spada C A, Hayes J G, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis.  Eur Respir J. 2005;  25 96-103
• 253 Wells A U, Hansell D M, Rubens M B, Cailes J B, Black C M, du Bois R M. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison.  Am J Respir Crit Care Med. 1997;  155 1657-1664
• 254 Daniil Z D, Gilchrist F C, Nicholson A G et al.. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med. 1999;  160 899-905
• 255 Flaherty K R, Thwaite E L, Kazerooni E A et al.. Radiological versus histological diagnosis in UIP and NSIP: survival implications.  Thorax. 2003;  58 143-148
• 256 Watters L C, King T E, Schwarz M I, Waldron J A, Stanford R E, Cherniack R M. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.  Am Rev Respir Dis. 1986;  133 97-103
• 257 Perez A, Rogers R M, Dauber J H. The prognosis of idiopathic pulmonary fibrosis.  Am J Respir Cell Mol Biol. 2003;  29(Suppl 3) S19-S26
• 258 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.  Am J Respir Crit Care Med. 2003;  167 735-740
• 259 Leuchte H H, Neurohr C, Baumgartner R et al.. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.  Am J Respir Crit Care Med. 2004;  170 360-365
• 260 Harari S, Simonneau G, De Juli E et al.. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation.  J Heart Lung Transplant. 1997;  16 460-463
• 261 Ghofrani H A, Wiedemann R, Rose F et al.. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.  Lancet. 2002;  360 895-900
• 262 Olschewski H, Ghofrani H A, Walmrath D et al.. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.  Am J Respir Crit Care Med. 1999;  160 600-607
• 263 Bando K, Keenan R J, Paradis I L et al.. Impact of pulmonary hypertension on outcome after single-lung transplantation.  Ann Thorac Surg. 1994;  58 1336-1342
• 264 Huerd S S, Hodges T N, Grover F L et al.. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation.  J Thorac Cardiovasc Surg. 2000;  119 458-465
• 265 Whelan T P, Dunitz J M, Kelly R F et al.. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis.  J Heart Lung Transplant. 2005;  24 1269-1274
• 266 Keane M P, Lynch III J P. Pleuropulmonary manifestations of systemic lupus erythematosus.  Thorax. 2000;  55 159-166
• 267 Lynch III J P, Orens J, Kazerooni E A. Collagen vascular diseases. In: Sperber M Diffuse Lung Diseases: A Comprehensive Clinical-Radiological Overview. London; Springer-Verlag 1999: 325-355
• 268 Marie I, Hachulla E, Hatron P Y et al.. Polymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors of prognosis.  J Rheumatol. 2001;  28 2230-2237
• 269 Douglas W W, Tazelaar H D, Hartman T E et al.. Polymyositis-dermatomyositis-associated interstitial lung disease.  Am J Respir Crit Care Med. 2001;  164 1182-1185
• 270 Tazelaar H D, Viggiano R W, Pickersgill J, Colby T V. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings.  Am Rev Respir Dis. 1990;  141 727-733
• 271 Tashkin D P, Elashoff R, Clements P J et al.. Cyclophosphamide versus placebo in scleroderma lung disease.  N Engl J Med. 2006;  354 2655-2666
• 272 Deheinzelin D, Capelozzi V L, Kairalla R A, Barbas Filho J V, Saldiva P H, de Carvalho C R. Interstitial lung disease in primary Sjögren's syndrome: clinical-pathological evaluation and response to treatment.  Am J Respir Crit Care Med. 1996;  154(3 Pt 1) 794-799
• 273 Lynch III J, Baughman R, Sharma O. Extrapulmonary sarcoidosis.  Semin Respir Infect. 1998;  13 229-254
• 274 Lynch III J P, Kazerooni E A, Gay S E. Pulmonary sarcoidosis.  Clin Chest Med. 1997;  18 755-785
• 275 Newman L S, Rose C S, Maier L A. Sarcoidosis.  N Engl J Med. 1997;  336 1224-1234
• 276 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.  Am J Respir Crit Care Med. 1999;  160 736-755
• 277 Lynch III J P, White E. Pulmonary sarcoidosis. In: Costabel U, Drent M, guest Sarcoidosis European Respiratory Journal Monograph (volume:10 (monograph 32). 2005: 105-129
• 278 Judson M A, Baughman R P, Thompson B W et al.. Two year prognosis of sarcoidosis: the ACCESS experience.  Sarcoidosis Vasc Diffuse Lung Dis. 2003;  20 204-211
• 279 Baughman R P, Winget D B, Bowen E H, Lower E E. Predicting respiratory failure in sarcoidosis patients.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14 154-158
• 280 Judson M A. Lung transplantation for pulmonary sarcoidosis.  Eur Respir J. 1998;  11 738-744
• 281 Baughman R P, Sharma O P, Lynch III J P. Sarcoidosis: is therapy effective?.  Semin Respir Infect. 1998;  13 255-273
• 282 Gibson G J, Prescott R J, Muers M F et al.. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.  Thorax. 1996;  51 238-247
• 283 Baughman R P, Winget D B, Lower E E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 60-66
• 284 Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen.  Eur Respir J. 1999;  14 1117-1122
• 285 Baughman R P, Lower E E. Leflunomide for chronic sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2004;  21 43-48
• 286 Baltzan M, Mehta S, Kirkham T H, Cosio M G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis.  Am J Respir Crit Care Med. 1999;  160 192-197
• 287 Baughman R P, Lower E E. Infliximab for refractory sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2001;  18 70-74
• 288 Pettersen J A, Zochodne D W, Bell R B, Martin L, Hill M D. Refractory neurosarcoidosis responding to infliximab.  Neurology. 2002;  59 1660-1661
• 289 Katz J M, Bruno M K, Winterkorn J M, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab.  Arch Neurol. 2003;  60 426-430
• 290 Utz J P, Limper A H, Kalra S et al.. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.  Chest. 2003;  124 177-185
• 291 Khanna D, Liebling M R, Louie J S. Etanercept ameliorates sarcoidosis arthritis and skin disease.  J Rheumatol. 2003;  30 1864-1867
• 292 Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.  Ann Rheum Dis. 2004;  63 318-320
• 293 Alhamad E H, Lynch III J P, Martinez F J. Pulmonary function tests in interstitial lung disease: what role do they have?.  Clin Chest Med. 2001;  22 715-750
• 294 Bradvik I, Wollmer P, Blom-Bulow B, Albrechtsson U, Jonson B. Lung mechanics and gas exchange in steroid treated pulmonary sarcoidosis: a seven year follow-up.  Sarcoidosis. 1991;  8 105-114
• 295 Lynch III J P, Kazerooni E. Sarcoidosis. In: Sperber M Radiologic Diagnosis of Chest Disease. 2nd ed. London; Springer-Verlag 2001: 193-220
• 296 Hennebicque A S, Nunes H, Brillet P Y, Moulahi H, Valeyre D, Brauner M W. CT findings in severe thoracic sarcoidosis.  Eur Radiol. 2005;  15 23-30
• 297 Lynch III J P. Computed tomographic scanning in sarcoidosis.  Semin Respir Crit Care Med. 2003;  24 393-418
• 298 Hadjiliadis D, Sporn T A, Perfect J R, Tapson V F, Davis R D, Palmer S M. Outcome of lung transplantation in patients with mycetomas.  Chest. 2002;  121 128-134
• 299 Arcasoy S M, Christie J D, Pochettino A et al.. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation.  Chest. 2001;  120 873-880
• 300 Shorr A F, Davies D B, Nathan S D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation.  Chest. 2003;  124 922-928
• 301 Shorr A F, Helman D L, Davies D B, Nathan S D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.  Eur Respir J. 2005;  25 783-788
• 302 Preston I R, Klinger J R, Landzberg M J, Houtchens J, Nelson D, Hill N S. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.  Chest. 2001;  120 866-872
• 303 Gluskowski J, Hawrylkiewicz I, Zych D, Zielinski J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis.  Eur Respir J. 1990;  3 403-407
• 304 Shorr A F, Helman D L, Davies D B, Nathan S D. Sarcoidosis, race, and short-term outcomes following lung transplantation.  Chest. 2004;  125 990-996
• 305 Young C J, Gaston R S. African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes.  Am J Med Sci. 2002;  323 94-99
• 306 Nair S, Eustace J, Thuluvath P J. Effect of race on outcome of orthotopic liver transplantation: a cohort study.  Lancet. 2002;  359 287-293
• 307 Martinez F J, Orens J B, Deeb M, Brunsting L A, Flint A, Lynch III J P. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation.  Chest. 1994;  106 1597-1599
• 308 Collins J, Hartman M J, Warner T F et al.. Frequency and CT findings of recurrent disease after lung transplantation.  Radiology. 2001;  219 503-509
• 309 Tazi A, Soler P, Hance A J. Adult pulmonary Langerhans' cell histiocytosis.  Thorax. 2000;  55 405-416
• 310 Friedman P J, Liebow A A, Sokoloff J. Eosinophilic granuloma of lung: clinical aspects of primary histiocytosis in the adult.  Medicine (Baltimore). 1981;  60 385-396
• 311 Vassallo R, Ryu J H, Colby T V, Hartman T, Limper A H. Pulmonary Langerhans'-cell histiocytosis.  N Engl J Med. 2000;  342 1969-1978
• 312 Vassallo R, Ryu J H, Schroeder D R, Decker P A, Limper A H. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults.  N Engl J Med. 2002;  346 484-490
• 313 Travis W D, Borok Z, Roum J H et al.. Pulmonary Langerhans' cell granulomatosis (histiocytosis X): a clinicopathologic study of 48 cases.  Am J Surg Pathol. 1993;  17 971-986
• 314 Basset F, Corrin B, Spencer H et al.. Pulmonary histiocytosis X.  Am Rev Respir Dis. 1978;  118 811-820
• 315 Tazi A. Adult pulmonary Langerhans' cell histiocytosis.  Eur Respir J. 2006;  27 1272-1285
• 316 McClain K L, Gonzalez J M, Jonkers R, De Juli E, Egeler M. Need for a cooperative study: pulmonary Langerhans' cell histiocytosis and its management in adults.  Med Pediatr Oncol. 2002;  39 35-39
• 317 Crausman R S, Jennings C A, Tuder R M, Ackerson L M, Irvin C G, King Jr T E. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology.  Am J Respir Crit Care Med. 1996;  153 426-435
• 318 Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord.  Eur Respir J. 1996;  9 2002-2006
• 319 Howarth D M, Gilchrist G S, Mullan B P, Wiseman G A, Edmonson J H, Schomberg P J. Langerhans' cell histiocytosis: diagnosis, natural history, management, and outcome.  Cancer. 1999;  85 2278-2290
• 320 Arico M, Girschikofsky M, Genereau T et al.. Langerhans' cell histiocytosis in adults: report from the International Registry of the Histiocyte Society.  Eur J Cancer. 2003;  39 2341-2348
• 321 Chaowalit N, Pellikka P A, Decker P A et al.. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans' cell histiocytosis.  Mayo Clin Proc. 2004;  79 1269-1275
• 322 Fartoukh M, Humbert M, Capron F et al.. Severe pulmonary hypertension in histiocytosis X.  Am J Respir Crit Care Med. 2000;  161 216-223
• 323 Mogulkoc N, Veral A, Bishop P W, Bayindir U, Pickering C A, Egan J J. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation.  Chest. 1999;  115 1452-1455
• 324 Saven A, Burian C. Cladribine activity in adult Langerhans'-cell histiocytosis.  Blood. 1999;  93 4125-4130
• 325 Etienne B, Bertocchi M, Gamondes J P et al.. Relapsing pulmonary Langerhans' cell histiocytosis after lung transplantation.  Am J Respir Crit Care Med. 1998;  157 288-291
• 326 Gabbay E, Dark J H, Ashcroft T et al.. Recurrence of Langerhans' cell granulomatosis following lung transplantation.  Thorax. 1998;  53 326-327
• 327 Habbib S B, Congelton J, Carr D, Mickey M. Recurrence of Langerhans' cell histiocytosis following bilateral lung transplantation.  Thorax. 1998;  53 323-325
• 328 Urban T, Lazor R, Lacronique J et al.. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P).  Medicine (Baltimore). 1999;  78 321-337
• 329 Johnson S R. Lymphangioleiomyomatosis.  Eur Respir J. 2006;  27 1056-1065
• 330 Chu S C, Horiba K, Usuki J et al.. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis.  Chest. 1999;  115 1041-1052
• 331 Johnson S. Rare diseases, I: Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.  Thorax. 1999;  54 254-264
• 332 Johnson S R, Tattersfield A E. Clinical experience of lymphangioleiomyomatosis in the UK.  Thorax. 2000;  55 1052-1057
• 333 Taylor J R, Ryu J, Colby T V, Raffin T A. Lymphangioleiomyomatosis: clinical course in 32 patients.  N Engl J Med. 1990;  323 1254-1260
• 334 Bernstein S M, Newell Jr J D, Adamczyk D, Mortenson R L, King Jr T E, Lynch D A. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?.  Am J Respir Crit Care Med. 1995;  152(6 Pt 1) 2138-2143
• 335 Avila N A, Kelly J A, Chu S C, Dwyer A J, Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings.  Radiology. 2000;  216 147-153
• 336 Matsui K, Tatsuguchi A, Valencia J et al.. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases.  Hum Pathol. 2000;  31 1242-1248
• 337 Costello L C, Hartman T E, Ryu J H. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.  Mayo Clin Proc. 2000;  75 591-594
• 338 Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors.  Am J Respir Crit Care Med. 1995;  151(2 Pt 1) 527-533
• 339 Johnson S R, Tattersfield A E. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.  Am J Respir Crit Care Med. 1999;  160 628-633
• 340 Crausman R S, Lynch D A, Mortenson R L et al.. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.  Chest. 1996;  109 131-137
• 341 Lazor R, Valeyre D, Lacronique J, Wallaert B, Urbane T, Cordier J F. Low initial KCO predicts rapid FEV₁ decline in pulmonary lymphangioleiomyomatosis.  Respir Med. 2004;  98 536-541
• 342 Taveira-Dasilva A M, Stylianou M P, Hedin C J, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.  Chest. 2004;  126 1867-1874
• 343 Johnson S R, Whale C I, Hubbard R B, Lewis S A, Tattersfield A E. Survival and disease progression in UK patients with lymphangioleiomyomatosis.  Thorax. 2004;  59 800-803
• 344 Boehler A. Lung transplantation for cystic lung diseases: lymphangioleiomyomatosis, histiocytosis X, and sarcoidosis.  Semin Respir Crit Care Med. 2001;  22 509-516
• 345 Ryu J H, Doerr C H, Fisher S D, Olson E J, Sahn S A. Chylothorax in lymphangioleiomyomatosis.  Chest. 2003;  123 623-627
• 346 Hertz M I, Boucek M M, Deng M C et al.. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2005 annual reports.  J Heart Lung Transplant. 2005;  24 939-944
• 347 Boehler A, Speich R, Russi E W, Weder W. Lung transplantation for lymphangioleiomyomatosis.  N Engl J Med. 1996;  335 1275-1280
• 348 Pechet T T, Meyers B F, Guthrie T J et al.. Lung transplantation for lymphangioleiomyomatosis.  J Heart Lung Transplant. 2004;  23 301-308
• 349 NHLBI . Workshop Summary. Report of workshop on lymphangioleiomyomatosis. National Heart, Lung, and Blood Institute.  Am J Respir Crit Care Med. 1999;  159 679-683
• 350 Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis.  Hum Pathol. 2003;  34 95-98
• 351 Karbowniczek M, Astrinidis A, Balsara B R et al.. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism.  Am J Respir Crit Care Med. 2003;  167 976-982
• 352 Farber H W, Loscalzo J. Pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1655-1665
• 353 Perros F, Dorfmuller P, Humbert M. Current insights on the pathogenesis of pulmonary arterial hypertension.  Semin Respir Crit Care Med. 2005;  26 355-364
• 354 Hopkins W E, Ochoa L L, Richardson G W, Trulock E P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.  J Heart Lung Transplant. 1996;  15(1 Pt 1) 100-105
• 355 Hopkins W E, Waggoner A D. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.  Am J Cardiol. 2002;  89 34-38
• 356 Rich S, Shillington A, McLaughlin V. Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.  Am J Cardiol. 2003;  92 1366-1368
• 357 Rubin L J, Badesch D B. Evaluation and management of the patient with pulmonary arterial hypertension.  Ann Intern Med. 2005;  143 282-292
• 358 Chakinala M M. Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.  Semin Respir Crit Care Med. 2005;  26 409-416
• 359 Loyd J E. Genetics and pulmonary hypertension.  Chest. 2002;  122(Suppl 6) 284S-286S
• 360 Lane K B, Machado R D, Pauciulo M W et al.. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.  Nat Genet. 2000;  26 81-84
• 361 Deng Z, Haghighi F, Helleby L et al.. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.  Am J Respir Crit Care Med. 2000;  161(3 Pt 1) 1055-1059
• 362 Morse J H. Genetic studies of pulmonary arterial hypertension.  Lupus. 2003;  12 209-212
• 363 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
• 364 Kawut S M, Taichman D B, Archer-Chicko C L, Palevsky H I, Kimmel S E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.  Chest. 2003;  123 344-350
• 365 Menzel T, Kramm T, Bruckner A, Mohr-Kahaly S, Mayer E, Meyer J. Quantitative assessment of right ventricular volumes in severe chronic thromboembolic pulmonary hypertension using transthoracic three-dimensional echocardiography: changes due to pulmonary thromboendarterectomy.  Eur J Echocardiogr. 2002;  3 67-72
• 366 Nunes H, Humbert M, Sitbon O et al.. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  167 1433-1439
• 367 Pellicelli A M, D'Ambrosio C, Vizza C D et al.. HIV-related pulmonary hypertension: from pathogenesis to clinical aspects.  Acta Cardiol. 2004;  59 323-330
• 368 Tan H P, Markowitz J S, Montgomery R A et al.. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.  Liver Transpl. 2001;  7 745-749
• 369 Yung D, Widlitz A C, Rosenzweig E B, Kerstein D, Maislin G, Barst R J. Outcomes in children with idiopathic pulmonary arterial hypertension.  Circulation. 2004;  110 660-665
• 370 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
• 371 Galie N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 372 Simonneau G, Galie N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
• 373 Morrell N W, Yang X, Upton P D et al.. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta and bone morphogenetic proteins.  Circulation. 2001;  104 790-795
• 374 McLaughlin V V, Presberg K W, Doyle R L et al.. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 78S-92S
• 375 Gammie J S, Keenan R J, Pham S M et al.. Single- versus double-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1998;  115 397-402 discussion 403
• 376 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 377 Magnani B, Galie N. Prostacyclin in primary pulmonary hypertension.  Eur Heart J. 1996;  17 18-24
• 378 McLaughlin V V. Medical management of primary pulmonary hypertension.  Expert Opin Pharmacother. 2002;  3 159-165
• 379 Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension.  Am J Health Syst Pharm. 2004;  61 1107-1119
• 380 Simonneau G, Barst R J, Galie N et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 381 Galie N, Ghofrani H A, Torbicki A et al.. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
• 382 Rosas V, Conte J V, Yang S C et al.. Lung transplantation and systemic sclerosis.  Ann Transplant. 2000;  5 38-43
• 383 Pigula F A, Griffith B P, Zenati M A, Dauber J H, Yousem S A, Keenan R J. Lung transplantation for respiratory failure resulting from systemic disease.  Ann Thorac Surg. 1997;  64 1630-1634
• 384 Yeatman M, McNeil K, Smith J A et al.. Lung transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital.  J Heart Lung Transplant. 1996;  15 144-149
• 385 Levine S M, Anzueto A, Peters J I, Calhoon J H, Jenkinson S G, Bryan C L. Single-lung transplantation in patients with systemic disease.  Chest. 1994;  105 837-841
• 386 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med. 1992;  327 76-81
• 387 Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.  J Am Coll Cardiol. 1991;  18 1323-1327
• 388 Barst R J, Rubin L J, Long W A et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
• 389 Barst R J, Langleben D, Badesch D et al.. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.  J Am Coll Cardiol. 2006;  47 2049-2056
• 390 Barst R J, Langleben D, Frost A et al.. Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
• 391 Sandoval J, Gaspar J, Pulido T et al.. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment.  J Am Coll Cardiol. 1998;  32 297-304
• 392 Olsson J K, Zamanian R T, Feinstein J A, Doyle R L. Surgical and interventional therapies for pulmonary arterial hypertension.  Semin Respir Crit Care Med. 2004;  26 417-428
• 393 Frank H, Mlczoch J, Huber K, Schuster E, Gurtner H P, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.  Chest. 1997;  112 714-721
• 394 Rubin L J, Nicod P, Hillis L D, Firth B G. Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation.  Ann Intern Med. 1983;  99 433-438
• 395 Rosenzweig E B, Kerstein D, Barst R J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
• 396 Nagaya N, Uematsu M, Okano Y et al.. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.  J Am Coll Cardiol. 1999;  34 1188-1192
• 397 Galie N, Humbert M, Vachiery J L et al.. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
• 398 Hoeper M M, Schwarze M, Ehlerding S et al.. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.  N Engl J Med. 2000;  342 1866-1870
• 399 Olschewski H, Simonneau G, Galie N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 400 Tapson V F, Gomberg-Maitland M, McLaughlin V V et al.. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.  Chest. 2006;  129 683-688
• 401 Galie N, Badesch D, Oudiz R et al.. Ambrisentan therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2005;  46 529-535
• 402 McLaughlin V V, Sitbon O, Badesch D B et al.. Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
• 403 Ghofrani H A, Wiedemann R, Rose F et al.. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.  Ann Intern Med. 2002;  136 515-522
• 404 Sitbon O, Humbert M, Jais X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
• 405 Mikhail G, al-Kattan K, Banner N et al.. Long-term results of heart-lung transplantation for pulmonary hypertension.  Transplant Proc. 1997;  29(1-2) 633
• 406 Bridges N D, Mallory Jr G B, Huddleston C B, Canter C E, Sweet S C, Spray T L. Lung transplantation in children and young adults with cardiovascular disease.  Ann Thorac Surg. 1995;  59 813-820 discussion 320-321
• 407 Pasque M K, Trulock E P, Cooper J D et al.. Single-lung transplantation for pulmonary hypertension. Single institution experience in 34 patients.  Circulation. 1995;  92 2252-2258
• 408 Bando K, Armitage J M, Paradis I L et al.. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1994;  108 1056-1065
• 409 Conte J V, Borja M J, Patel C B, Yang S C, Jhaveri R M, Orens J B. Lung transplantation for primary and secondary pulmonary hypertension.  Ann Thorac Surg. 2001;  72 1673-1679 discussion 1679-1680
• 410 Mendeloff E N, Meyers B F, Sundt T M et al.. Lung transplantation for pulmonary vascular disease.  Ann Thorac Surg. 2002;  73 209-217 discussion 217-219
• 411 Davis Jr R D, Trulock E P, Manley J et al.. Differences in early results after single-lung transplantation. Washington University Lung Transplant Group.  Ann Thorac Surg. 1994;  58 1327-1334 discussion 1334-1335
• 412 Griffith B P, Hardesty R L, Trento A et al.. Heart-lung transplantation: lessons learned and future hopes.  Ann Thorac Surg. 1987;  43 6-16
• 413 Pasque M K, Trulock E P, Kaiser L R, Cooper J D. Single-lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up.  Circulation. 1991;  84 2275-2279
• 414 Katz W E, Gasior T A, Quinlan J J et al.. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension.  J Am Coll Cardiol. 1996;  27 384-391
• 415 Fremes S E, Patterson G A, Williams W G, Goldman B S, Todd T R, Maurer J. Single-lung transplantation and closure of patent ductus arteriosus for Eisenmenger's syndrome. Toronto Lung Transplant Group.  J Thorac Cardiovasc Surg. 1990;  100 1-5
• 416 Kreitmann B, Metras D, Badier M. Unilateral lung transplantation for Eisenmenger's syndrome.  J Thorac Cardiovasc Surg. 1992;  104 529-530
• 417 Lupinetti F M, Bolling S F, Bove E L et al.. Selective lung or heart-lung transplantation for pulmonary hypertension associated with congenital cardiac anomalies.  Ann Thorac Surg. 1994;  57 1545-1548 discussion 1549
• 418 Birsan T, Zuckermann Z, Artermiou O et al.. Bilateral lung transplantation for pulmonary hypertension.  Transplant Proc. 1997;  29 2892-2894
• 419 Levine S M, Jenkinson S G, Bryan C L et al.. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension.  Chest. 1992;  101 401-405
• 420 Christie J D, Kotloff R M, Ahya V N et al.. The effect of primary graft dysfunction on survival after lung transplantation.  Am J Respir Crit Care Med. 2005;  171 1312-1316
• 421 de Perrot M, Liu M, Waddell T K, Keshavjee S. Ischemia-reperfusion-induced lung injury.  Am J Respir Crit Care Med. 2003;  167 490-511
• 422 Anderson D C, Glazer H S, Semenkovich J W et al.. Lung transplant edema: chest radiography after lung transplantation-the first 10 days.  Radiology. 1995;  195 275-281
• 423 Khan S U, Salloum J, O'Donovan P B et al.. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response.  Chest. 1999;  116 187-194
• 424 Sleiman C, Mal H, Fournier M et al.. Pulmonary reimplantation response in single-lung transplantation.  Eur Respir J. 1995;  8 5-9
• 425 Chatila W M, Furukawa S, Gaughan J P, Criner G J. Respiratory failure after lung transplantation.  Chest. 2003;  123 165-173
• 426 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.  Ann Thorac Surg. 2000;  69 1681-1685
• 427 Thabut G, Vinatier I, Stern J B et al.. Primary graft failure following lung transplantation: predictive factors of mortality.  Chest. 2002;  121 1876-1882
• 428 Ueno T, Smith J A, Snell G I et al.. Bilateral sequential single-lung transplantation for pulmonary hypertension and Eisenmenger's syndrome.  Ann Thorac Surg. 2000;  69 381-387
• 429 Boujoukos A J, Martich G D, Vega J D, Keenan R J, Griffith B P. Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema.  J Heart Lung Transplant. 1997;  16 439-448
• 430 Kshettry V R, Kroshus T J, Savik K, Hertz M I, Bolman R M. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients.  Chest. 1996;  110 704-709
• 431 Chapelier A, Vouhe P, Macchiarini P et al.. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1993;  106 299-307
• 432 Birsan T, Kranz A, Mares P et al.. Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension.  J Heart Lung Transplant. 1999;  18 304-309
• 433 Soriano C M, Gaine S P, Conte J V, Fairman R P, White C, Rubin L J. Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction.  Chest. 1999;  116 564-566
• 434 Izbicki G, Shitrit D, Schechtman I et al.. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation.  J Heart Lung Transplant. 2005;  24 635-637
• 435 de Perrot M, Waddell T K, Chamberlain D, Hutcheon M, Keshavjee S. De novo pulmonary capillary hemangiomatosis occurring rapidly after bilateral lung transplantation.  J Heart Lung Transplant. 2003;  22 698-700